Renal Cell Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
Conditions: Clear Cell Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 Interventions: Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Computed Tomography; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Drug: Myrciaria dubia Prebiotic Supplement; Biological: Nivolumab Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Condition: Renal Cell Carcinoma Intervention: Drug: HS-10516 Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials